It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Microsatellite-instable (MSI), a predictive biomarker for immune checkpoint blockade (ICB) response, is caused by mismatch repair deficiency (MMRd) that occurs through genetic or epigenetic silencing of MMR genes. Here, we report a mechanism of MMRd and demonstrate that protein phosphatase 2A (PP2A) deletion or inactivation converts cold microsatellite-stable (MSS) into MSI tumours through two orthogonal pathways: (i) by increasing retinoblastoma protein phosphorylation that leads to E2F and DNMT3A/3B expression with subsequent DNA methylation, and (ii) by increasing histone deacetylase (HDAC)2 phosphorylation that subsequently decreases H3K9ac levels and histone acetylation, which induces epigenetic silencing of MLH1. In mouse models of MSS and MSI colorectal cancers, triple-negative breast cancer and pancreatic cancer, PP2A inhibition triggers neoantigen production, cytotoxic T cell infiltration and ICB sensitization. Human cancer cell lines and tissue array effectively confirm these signaling pathways. These data indicate the dual involvement of PP2A inactivation in silencing MLH1 and inducing MSI.
Microsatellite instability (MSI), caused by deficiency of the DNA mismatch repair system, has been associated with improved response to immune checkpoint blockade (ICB). Here the authors show that inactivation of protein phosphatase 2A induces a MSI status, promoting cytotoxic T cell infiltration and response to ICB in pre-clinical cancer models.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 China Medical University, Drug Development Center, Institute of New Drug Development, Taichung, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092); China Medical University Hospital, Integrative Stem Cell Center, Taichung, Taiwan (GRID:grid.411508.9) (ISNI:0000 0004 0572 9415)
2 China Medical University, Department of Biomedical Imaging and Radiological Science, Taichung, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092); China Medical University, Translation Research Core, China Medical University Hospital, Taichung, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092)
3 China Medical University, Proton Therapy and Science Center, China Medical University Hospital, Taichung, ROC (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092); Ministry of Health and Welfare, Lab of Precision Medicine, Feng-Yuan Hospital, Taichung, Taiwan (GRID:grid.454740.6)
4 China Medical University, Proton Therapy and Science Center, China Medical University Hospital, Taichung, ROC (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092)
5 China Medical University, Department of Colorectal Surgery, China Medical University Hospital, Taichung, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092); China Medical University, Department of Colorectal Surgery, China Medical University HsinChu Hospital, HsinChu, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092)
6 China Medical University, Drug Development Center, Institute of New Drug Development, Taichung, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092); China Medical University Hospital, Integrative Stem Cell Center, Taichung, Taiwan (GRID:grid.411508.9) (ISNI:0000 0004 0572 9415); China Medical University Hospital, Department of Orthopaedics, Taichung, Taiwan (GRID:grid.411508.9) (ISNI:0000 0004 0572 9415)